# A Single-Arm Study Evaluating the Effectiveness and Safety of Suzetrigine (SUZ) for Acute Pain After Aesthetic or Reconstructive Surgeries

> **NCT06887972** · PHASE4 · COMPLETED · sponsor: **Vertex Pharmaceuticals Incorporated** · enrollment: 100 (actual)

## Conditions studied

- Acute Pain

## Interventions

- **DRUG:** Suzetrigine

## Key facts

- **NCT ID:** NCT06887972
- **Lead sponsor:** Vertex Pharmaceuticals Incorporated
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2025-03-21
- **Primary completion:** 2025-10-24
- **Final completion:** 2025-11-07
- **Target enrollment:** 100 (ACTUAL)
- **Last updated:** 2025-12-15


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06887972

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06887972, "A Single-Arm Study Evaluating the Effectiveness and Safety of Suzetrigine (SUZ) for Acute Pain After Aesthetic or Reconstructive Surgeries". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT06887972. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*